1 Table of Contents

- 1.1 List of Tables
- 1.2 List of Figures

2 Diabetic Foot Ulcer Therapeutics - Introduction

- 2.1 Overview
- 2.1.1 Diabetic Foot Ulcer Classification Systems
- 2.2 Epidemiology
- 2.2.1 Historic Epidemiology (2006-2011)
- 2.2.2 Forecast Epidemiology (2011-2019)
- 2.3 Prognosis
- 2.4 Etiology
- 2.5 Symptoms
- 2.6 Diagnosis
- 2.6.1 History
- 2.6.2 Neurologic Examination
- 2.6.3 Vascular Examination
- 2.6.4 Musculoskeletal Examination
- 2.6.5 Wound Evaluation
- 2.6.6 Laboratory Testing and Imaging Studies
- 2.7 Pathophysiology
- 2.8 Treatment and Management Pattern
- 2.8.1 Infection Control
- 2.8.2 Mechanical Load Relief
- 2.8.3 Wound Care/Debridement
- 2.8.4 Blood Glucose Control
- 2.8.5 Patient Education
- 2.9 Referral Pathway
- 2.10 GlobalData Pipeline Report Guidance

3 Diabetic Foot Ulcer Therapeutics - Market Characterization

- 3.1 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) Global
- 3.2 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) Global
- 3.3 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) The US
- 3.4 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) The US
- 3.5 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) France
- 3.6 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) France
- 3.7 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) Germany
- 3.8 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) Germany
- 3.9 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) Italy
- 3.10 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) Italy
- 3.11 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) Spain
- 3.12 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) Spain
- 3.13 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) The UK
- 3.14 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) The UK
- 3.15 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) Japan
- 3.16 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) Japan
- 3.17 Drivers and Barriers for the Diabetic Foot Ulcer Therapeutics Market

- 3.17.1 Drivers of the Diabetic Foot Ulcer Therapeutics Market
- 3.17.2 Barriers for the Diabetic Foot Ulcer Therapeutics Market
- 3.18 Opportunity and Unmet Need
- 3.19 Key Takeaway

4 Diabetic Foot Ulcer Therapeutics - Competitive Assessment

- 4.1 Overview
- 4.2 Strategic Competitor Assessment
- 4.3 Product Profiles for the Major Marketed Products in the Diabetic Foot Ulcer

Therapeutics Market

- 4.4 Anti-infectives
- 4.4.1 Invanz (ertapenem)
- 4.4.2 Zosyn (piperacillin/tazobactam)
- 4.4.3 Zyvox (linezolid)
- 4.5 Wound-healing Products
- 4.5.1 Regranex (becaplermin)
- 4.6 Key Takeaway

5 Diabetic Foot Ulcer Therapeutics - Pipeline Assessment

- 5.1 Overview
- 5.2 Strategic Pipeline Assessment
- 5.3 Diabetic Foot Ulcer Therapeutics Pipeline Analysis by Phase of Development
- 5.3.1 Diabetic Foot Ulcer Therapeutics Phase III Pipeline
- 5.3.2 Diabetic Foot Ulcer Therapeutics Phase II Pipeline
- 5.3.3 Diabetic Foot Ulcer Therapeutics Phase I Pipeline
- 5.3.4 Diabetic Foot Ulcer Therapeutics Preclinical and Discovery Pipeline
- 5.4 Diabetic Foot Ulcer Therapeutics Pipeline by Mechanism of Action
- 5.5 Technology Trends Analytical Framework
- 5.6 Profiles of Promising Drugs
- 5.6.1 CVBT-141B (FGF-1)
- 5.6.2 Fragmin (dalteparin sodium)
- 5.6.3 Trafermin
- 5.6.4 Heberprot-P
- 5.6.5 HO/03/03
- 5.6.6 CureXcell
- 5.7 Key Takeaway

6 Diabetic Foot Ulcer Therapeutics - Clinical Trial Mapping

- 6.1 Clinical Trials by Region and Country
- 6.2 Clinical Trials by Phase of Clinical Development
- 6.3 Clinical Trials by Trial Status
- 6.4 Clinical Trials by Sponsors
- 6.5 Top Companies Participating in Diabetic Foot Ulcer Therapeutics Clinical Trials

7 Diabetic Foot Ulcer Therapeutics - Strategic Assessment

- 7.1 Key Events Impacting the Future Market
- 7.2 Future Market Competition Scenario

8 Diabetic Foot Ulcer Therapeutics - Future Players

- 8.1 Introduction
- 8.2 Company Profiles

- 8.2.1 Pfizer Inc.
- 8.2.2 Cardiovascular Biotherapeutics, Inc.
- 8.2.3 HealOr Ltd.
- 8.2.4 MacroCure Ltd.
- 8.2.5 Other Companies in the Pipeline

9 Diabetic Foot Ulcer Therapeutics - Licensing and Partnership Deals

10 Diabetic Foot Ulcer Therapeutics - Appendix

- 10.1 Market Definitions
- 10.2 Abbreviations
- 10.3 Bibliography
- 10.4 Physicians and Specialists Included in this Study
- 10.5 Research Methodology
- 10.5.1 Coverage
- 10.5.2 Secondary Research
- 10.5.3 Forecasting
- 10.5.4 Primary Research
- 10.5.5 Expert Panel Validation
- 10.6 Contact Us
- 10.7 Disclaimer

1.1 List of Tables

- Table 1: Diabetic Foot Ulcer Wagner-Meggitt Classification
- Table 2: The University of Texas Diabetic Wound Classification System
- Table 3: Diabetic Foot Ulcer, Global, Prevalence Population, 2006-2011
- Table 4: Diabetic Foot Ulcer, Global, Prevalence Population, 2011-2019
- Table 5: Diabetic Foot Ulcer Risk Factors
- Table 6: Diabetic Foot Infections Empirical Antibiotic Regimens
- Table 7: Diabetic Foot Infection Therapeutics Market, Global, Revenue (\$m), 2006-2011
- Table 8: Wound-healing Therapeutics Market, Global, Revenue (\$m), 2006-2011
- Table 9: Diabetic Foot Infection Therapeutics Market, Global, Forecast (\$m), 2011-2019
- Table 10: Wound-healing Therapeutics Market, Global, Forecast (\$m), 2011-2019
- Table 11: Diabetic Foot Infection Therapeutics Market, The US, Revenue (\$m), 2006-2011
- Table 12: Wound-healing Therapeutics Market, The US, Revenue (\$m), 2006-2011
- Table 13: Diabetic Foot Infection Therapeutics Market, The US, Forecast (\$m), 2011-2019
- Table 14: Wound-healing Therapeutics Market, The US, Forecast (\$m), 2011-2019
- Table 15: Diabetic Foot Infection Therapeutics Market, France, Revenue (\$m), 2006-2011
- Table 16: Wound-healing Therapeutics Market, France, Revenue (\$m), 2006-2011
- Table 17: Diabetic Foot Infection Therapeutics Market, France, Forecast (\$m), 2011-2019
- Table 18: Wound-healing Therapeutics Market, France, Forecast (\$m), 2011-2019
- Table 19: Diabetic Foot Infection Therapeutics Market, Germany, Revenue (\$m), 2006-2011
- Table 20: Wound-healing Therapeutics Market, Germany, Revenue (\$m), 2006-2011

- Table 21: Diabetic Foot Infection Therapeutics Market, Germany, Forecast (\$m), 2011-2019
- Table 22: Wound-healing Therapeutics Market, Germany, Forecast (\$m), 2011-2019
- Table 23: Diabetic Foot Infection Therapeutics Market, Italy, Revenue (\$m), 2006-2011
- Table 24: Wound-healing Therapeutics Market, Italy, Revenue (\$m), 2006-2011
- Table 25: Diabetic Foot Infection Therapeutics Market, Italy, Forecast (\$m), 2011-2019
- Table 26: Wound-healing Therapeutics Market, Italy, Forecast (\$m), 2011-2019
- Table 27: Diabetic Foot Infection Therapeutics Market, Spain, Revenue (\$m), 2006-2011
- Table 28: Wound-healing Therapeutics Market, Spain, Revenue (\$m), 2006-2011
- Table 29: Diabetic Foot Infection Therapeutics Market, Spain, Forecast (\$m), 2011-2019
- Table 30: Wound-healing Therapeutics Market, Spain, Forecast (\$m), 2011-2019
- Table 31: Diabetic Foot Infection Therapeutics Market, The UK, Revenue (\$m), 2006-2011
- Table 32: Wound-healing Therapeutics Market, The UK, Revenue (\$m), 2006-2011
- Table 33: Diabetic Foot Infection Therapeutics Market, The UK, Forecast (\$m), 2011-2019
- Table 34: Wound-healing Therapeutics Market, The UK, Forecast (\$m), 2011-2019
- Table 35: Diabetic Foot Infection Therapeutics Market, Japan, Revenue (\$m), 2006-2011
- Table 36: Wound-healing Therapeutics Market, Japan, Revenue (\$m), 2006-2011
- Table 37: Diabetic Foot Infection Therapeutics Market, Japan, Forecast (\$m), 2011-2019
- Table 38: Wound-healing Therapeutics Market, Japan, Forecast (\$m), 2011-2019
- Table 39: Diabetic Foot Ulcer Therapeutics Phase III Pipeline, 2012
- Table 40: Diabetic Foot Ulcer Therapeutics Phase II Pipeline, 2012
- Table 41: Diabetic Foot Ulcer Therapeutics Phase I Pipeline, 2012
- Table 42: Diabetic Foot Ulcer Therapeutics Preclinical and Discovery Pipeline, 2012
- Table 43: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials, 2012
- Table 44: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Phase, 2012
- Table 45: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Status of Development, 2012
- Table 46: Diabetic Foot Ulcer Therapeutics, Global, Overall Sponsors, 2012
- Table 47: Diabetic Foot Ulcer Therapeutics, Global, Prominent Sponsors, 2012
- Table 48: Diabetic Foot Ulcer Therapeutics, Global, Top Ten Companies by Phase, 2012
- Table 49: Pfizer, Inc. Diabetic Foot Ulcer Pipeline Products, 2012
- Table 50: Cardiovascular Biotherapeutics, Inc. DFU Pipeline Products, 2012
- Table 51: HealOr Ltd. DFU Pipeline Products, 2012
- Table 52: MacroCure Ltd. DFU Pipeline Products, 2012
- Table 53: Diabetic Foot Ulcer Therapeutics Other Companies in the Pipeline, 2012
- Table 54: Diabetic Foot Ulcer Therapeutics, Licensing and Partnership Deals, 2012

1.2 List of Figures

- Figure 1: The University of Texas Diabetic Wound Classification System
- Figure 2: Diabetic Foot Ulcer Pathophysiology
- Figure 3: Diabetic Foot Infections Antibiotic Use According to Clinical Severity
- Figure 4: Diabetic Foot Ulcer Referral Pathway
- Figure 5: Diabetic Foot Infection Therapeutics Market, Global, Revenue (\$m), 2006-2011
- Figure 6: Wound-healing Therapeutics Market, Global, Revenue (\$m), 2006-2011

- Figure 7: Diabetic Foot Infection Therapeutics Market, Global, Forecast (\$m), 2011-2019
- Figure 8: Wound-healing Therapeutics Market, Global, Forecast (\$m), 2011-2019
- Figure 9: Diabetic Foot Infection Therapeutics Market, The US, Revenue (\$m), 2006-2011
- Figure 10: Wound-healing Therapeutics Market, The US, Revenue (\$m), 2006-2011
- Figure 11: Diabetic Foot Infection Therapeutics Market, The US, Forecast (\$m), 2011-2019
- Figure 12: Wound-healing Therapeutics Market, The US, Forecast (\$m), 2011-2019
- Figure 13: Diabetic Foot Infection Therapeutics Market, France, Revenue (\$m), 2006-2011
- Figure 14: Wound-healing Therapeutics Market, France, Revenue (\$m), 2006-2011
- Figure 15: Diabetic Foot Infection Therapeutics Market, France, Forecast (\$m), 2011-2019
- Figure 16: Wound-healing Therapeutics Market, France, Forecast (\$m), 2011-2019
- Figure 17: Diabetic Foot Infection Therapeutics Market, Germany, Revenue (\$m), 2006-2011
- Figure 18: Wound-healing Therapeutics Market, Germany, Revenue (\$m), 2006-2011
- Figure 19: Diabetic Foot Infection Therapeutics Market, Germany, Forecast (\$m), 2011-2019
- Figure 20: Wound-healing Therapeutics Market, Germany, Forecast (\$m), 2011-2019
- Figure 21: Diabetic Foot Infection Therapeutics Market, Italy, Revenue (\$m), 2006-2011
- Figure 22: Wound-healing Therapeutics Market, Italy, Revenue (\$m), 2006-2011
- Figure 23: Diabetic Foot Infection Therapeutics Market, Italy, Forecast (\$m), 2011-2019
- Figure 24: Wound-healing Therapeutics Market, Italy, Forecast (\$m), 2011-2019
- Figure 25: Diabetic Foot Infection Therapeutics Market, Spain, Revenue (\$m), 2006-2011
- Figure 26: Wound-healing Therapeutics Market, Spain, Revenue (\$m), 2006-2011
- Figure 27: Diabetic Foot Infection Therapeutics Market, Spain, Forecast (\$m), 2011-2019
- Figure 28: Wound-healing Therapeutics Market, Spain, Forecast (\$m), 2011-2019
- Figure 29: Diabetic Foot Infection Therapeutics Market, The UK, Revenue (\$m), 2006-2011
- Figure 30: Wound-healing Therapeutics Market, The UK, Revenue (\$m), 2006-2011
- Figure 31: Diabetic Foot Infection Therapeutics Market, The UK, Forecast (\$m), 2011-2019
- Figure 32: Wound-healing Therapeutics Market, The UK, Forecast (\$m), 2011-2019
- Figure 33: Diabetic Foot Infection Therapeutics Market, Japan, Revenue (\$m), 2006-2011
- Figure 34: Wound-healing Therapeutics Market, Japan, Revenue (\$m), 2006-2011
- Figure 35: Diabetic Foot Infection Therapeutics Market, Japan, Forecast (\$m), 2011-2019
- Figure 36: Wound-healing Therapeutics Market, Japan, Forecast (\$m), 2011-2019
- Figure 37: Diabetic Foot Ulcer Therapeutics Market, Drivers and Barriers, 2012
- Figure 38: Opportunity and Unmet Need in Diabetic Foot Infection Therapeutics Market, 2012
- Figure 39: Opportunity and Unmet Need in the Diabetic Foot Ulcer Wound-healing Therapeutics Market, 2012

- Figure 40: Strategic Competitor Assessment of the Marketed Products in Diabetic Foot Ulcer Therapeutics, 2012
- Figure 41: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2012
- Figure 42: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Phase of Development (%), 2012
- Figure 43: Technology Trends Analytics Framework, 2012
- Figure 44: Technology Trends Analytics Framework Description, 2012
- Figure 45: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Country, 2012
- Figure 46: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Phase (%), 2012
- Figure 47: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Status of Development (%), 2012
- Figure 48: Diabetic Foot Ulcer Therapeutics, Global, Overall Sponsors (%), 2012
- Figure 49: Diabetic Foot Ulcer Therapeutics, Global, Prominent Sponsors (%), 2012
- Figure 50: Diabetic Foot Ulcer Therapeutics, Global, Top Companies by Phase, 2012
- Figure 51: Diabetic Foot Ulcer Therapeutics Market, Impact Analysis, 2012
- Figure 52: Implications for Future Market Competition in the Diabetic Foot Ulcer Therapeutics Market, 2012
- Figure 53: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Company, 2012
- Figure 54: GlobalData Market Size Estimation
- Figure 55: GlobalData Market Forecasting Model